date:Mar 27, 2013
The U.S. Food and Drug Administration (FDA) has approved Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) to treat patients showing signs of botulism following documented or suspected exposure to botulinum neurotoxin. The product, which will be stored in Strategic National Stockpile for emergency preparedness and responses, is derived from horse plasma and contains a mixture of antibody fragments that neutralize all of the seven botulinum nerve toxin serotypes known to cause botulis